Immunotherapies have recently emerged as a therapeutic option for patients with NSCLC. Therapies have been approved for both first- and second-line treatments of NSCLC tumors with specific patterns of PD-L1 expression. Mayo Clinic Laboratories offers four PD-L1 clones for assessing patient response to specific therapies.
A Test in Focus
Anja Roden, M.D., Ph.D., gives an overview of PD-L1 testing in lung cancer. She discusses when this testing should be ordered, how this testing compares to previous testing approaches, and what clinical action can be taken due to the results of this testing.